Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.57 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.51 |
| ▸ | ATR | Q13535 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12529199 | 0.85 | MCHR1 (0.70) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL2889406 | 0.83 | MCHR1 (0.73) | L3MBTL3MCHR1ATR | |
| SCHEMBL2886450 | 0.80 | MCHR1 (0.58) | L3MBTL3MCHR1ATR | |
| SCHEMBL12532132 | 0.79 | MCHR1 (0.66) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL2885651 | 0.79 | ATR (0.57) | DEGS1L3MBTL3MCHR1ATR | |
| SCHEMBL12529849 | 0.79 | MCHR1 (0.70) | L3MBTL3MCHR1L3MBTL1 | |
| SCHEMBL12529873 | 0.77 | MCHR1 (0.72) | L3MBTL3MCHR1L3MBTL1 | |
| SCHEMBL1750064 | 0.77 | MCHR1 (0.71) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL2887653 | 0.76 | ATR (0.51) | L3MBTL3MCHR1ATRL3MBTL1 | |
| SCHEMBL2888035 | 0.76 | L3MBTL3 (0.50) | L3MBTL3MCHR1ATRL3MBTL1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | claimed |
| US-20020183518-A1 | Modulators of proteins with phosphotyrosine recognition units | ONTOGEN CORPORATION | 2002-12-05 | — | — | US | claimed |
| US-6388076-B1 | ANTIPROLIFERATIVE AGENTS; SKIN DISORDERS; OSTEOPOROSIS | ONTOGEN CORPORATION | 2002-05-14 | — | — | US | claimed |
| US-7842715-B2 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2082740-A2 | Use of imidazole derivatives as MDR modulators | Taiji Biomedical, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2027086-A2 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007136668-A9 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH CORP (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007136668-A2 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
| US-20020183518-A1 | Modulators of proteins with phosphotyrosine recognition units | ONTOGEN CORPORATION | 2002-12-05 | — | — | US | disclosed |
| US-6388076-B1 | ANTIPROLIFERATIVE AGENTS; SKIN DISORDERS; OSTEOPOROSIS | ONTOGEN CORPORATION | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | HRH4, HRH3, HRH2 | HDAC3 773/4885HDAC11 1507/4885HDAC8 1233/4885 |
| US-20020183518-A1 | Modulators of proteins with phosphotyrosine recognition units | PTPRC, PTPN4, PTPN1 | HDAC3 4222/4885HDAC11 4109/4885HDAC8 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.